CN120078760A - 治疗患有非小细胞肺癌的女性非吸烟者的方法 - Google Patents

治疗患有非小细胞肺癌的女性非吸烟者的方法 Download PDF

Info

Publication number
CN120078760A
CN120078760A CN202510278250.XA CN202510278250A CN120078760A CN 120078760 A CN120078760 A CN 120078760A CN 202510278250 A CN202510278250 A CN 202510278250A CN 120078760 A CN120078760 A CN 120078760A
Authority
CN
China
Prior art keywords
lung cancer
small cell
patient
cell lung
dithiobis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510278250.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿迪亚·库尔卡米
阿伦·阿塞坦比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanteng Pharmaceutical Co
Original Assignee
Lanteng Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanteng Pharmaceutical Co filed Critical Lanteng Pharmaceutical Co
Publication of CN120078760A publication Critical patent/CN120078760A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202510278250.XA 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法 Pending CN120078760A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
US62/815,762 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer
CN202080034238.XA CN113906010A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080034238.XA Division CN113906010A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Publications (1)

Publication Number Publication Date
CN120078760A true CN120078760A (zh) 2025-06-03

Family

ID=72427123

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510278250.XA Pending CN120078760A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法
CN202080034238.XA Pending CN113906010A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080034238.XA Pending CN113906010A (zh) 2019-03-08 2020-03-08 治疗患有非小细胞肺癌的女性非吸烟者的方法

Country Status (11)

Country Link
US (1) US20220168258A1 (cg-RX-API-DMAC7.html)
EP (1) EP3935043A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022525040A (cg-RX-API-DMAC7.html)
KR (1) KR20220047208A (cg-RX-API-DMAC7.html)
CN (2) CN120078760A (cg-RX-API-DMAC7.html)
AU (2) AU2020235823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017716A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132827A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010745A (cg-RX-API-DMAC7.html)
SG (1) SG11202109705YA (cg-RX-API-DMAC7.html)
WO (1) WO2020185640A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2249825T3 (en) * 2008-03-14 2016-01-11 Bionumerik Pharmaceuticals Inc Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Also Published As

Publication number Publication date
EP3935043A4 (en) 2023-01-11
EP3935043A1 (en) 2022-01-12
BR112021017716A2 (pt) 2021-11-16
AU2020235823A1 (en) 2021-11-04
SG11202109705YA (en) 2021-10-28
KR20220047208A (ko) 2022-04-15
JP2022525040A (ja) 2022-05-11
CN113906010A (zh) 2022-01-07
AU2025267367A1 (en) 2025-12-04
JP2025081338A (ja) 2025-05-27
US20220168258A1 (en) 2022-06-02
MX2021010745A (es) 2021-12-15
WO2020185640A1 (en) 2020-09-17
CA3132827A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
Monnet et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
RU2662298C2 (ru) Лечение рака комбинацией плинабулина и таксана
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、sti571に耐性または不耐性の慢性骨髄性白血病の治療
BR112019026486A2 (pt) tinostamustina para uso no tratamento de câncer de ovário
BR112019026474A2 (pt) compostos para tratar tnbc
CN111867678A (zh) 治疗黑色素瘤的方法
AU2015317856B2 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2025137692A1 (en) Combination of dimesna and pemetrexed to treat non-small cell lung cancer (nsclc)
CA3134156C (en) Chiauranib for treatment of small cell lung cancer
JP6802598B1 (ja) 抗がん剤の効果増強剤
US20220168258A1 (en) Method for treating female non-smokers with non-small cell lung cancer
EP2560648A2 (en) Method for treating pancreatic cancer
BR112020016073A2 (pt) Métodos e terapia de combinação para tratar câncer do trato biliar
TW202337897A (zh) 抗pd-1抗體和抗vegf-a抗體的藥物組合及其使用方法
de la Vega et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial
Gent et al. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin
Wachters et al. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC
JP2013510126A (ja) コリン含有医薬組成物
CN118354772A (zh) 治疗头颈癌的方法
TW202339753A (zh) 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物
WO2024022282A1 (zh) 吡啶胺化合物在特定ros1基因融合的非小细胞肺癌中的应用
TW202506120A (zh) Bet抑制劑及parp抑制劑於治療胰臟癌之用途
WO2021219137A1 (zh) 用于治疗met基因异常疾病的氨基吡啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination